The inherited retinal disease (IRD) community is keenly watching developments in gene therapy, and a recent announcement from Applied Genetic Technologies Corporation (AGTC) brings promising news. AGTC, a clinical-stage biotechnology company deeply involved in developing gene therapies for rare ophthalmic diseases, has appointed biopharmaceutical industry leader James Robinson to its Board of Directors. This move is significant as it brings extensive commercial and operational expertise to a company focused on bringing potential treatments to patients with IRDs.
Key Leadership to Advance IRD Therapies
On December 6, 2021, AGTC announced the addition of James Robinson to its Board of Directors. Mr. Robinson, who was President and Chief Executive Officer (CEO) of Urovant Sciences at the time of his appointment, brings over 28 years of experience in the biopharmaceutical industry. His background includes successfully building and leading organizations from their early development stages through commercialization. Prior to Urovant Sciences, he held leadership roles at Paragon Biosciences and Alkermes, overseeing global commercial operations, new product planning, manufacturing, and business development.
Sue Washer, AGTC's President and CEO, highlighted Mr. Robinson's